Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE SODIUM PHOSPHATE versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE SODIUM PHOSPHATE versus STERI STAT.
HYDROCORTISONE SODIUM PHOSPHATE vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone sodium phosphate is a corticosteroid that binds to the glucocorticoid receptor, leading to regulation of gene transcription. It inhibits phospholipase A2, reducing pro-inflammatory mediators such as prostaglandins and leukotrienes. It also suppresses immune cell migration and cytokine production.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
100-500 mg intravenously or intramuscularly every 2-6 hours as needed for acute conditions; typical dose 100 mg IV/IM every 8 hours.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Terminal elimination half-life approximately 1.5–2 hours; in adrenal insufficiency, dose interval is 8 hours due to HPA axis suppression considerations.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: primarily as inactive metabolites, <1% unchanged; hepatic metabolism to tetrahydrocortisone and glucuronide conjugates; biliary/fecal excretion negligible.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid